Galmed Pharmaceuticals Analyst Ratings
Galmed Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/24/2023 | 247.83% | Maxim Group | → $4 | Upgrades | Hold → Buy |
| 08/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/08/2022 | -13.04% | Canaccord Genuity | $5 → $1 | Downgrades | Buy → Hold |
| 05/18/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 05/03/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 05/03/2022 | 334.78% | Raymond James | $14 → $5 | Maintains | Outperform |
| 05/17/2021 | 1726.09% | Canaccord Genuity | $20 → $21 | Maintains | Buy |
| 03/19/2021 | 2073.91% | HC Wainwright & Co. | $29 → $25 | Maintains | Buy |
| 01/08/2021 | 1378.26% | Raymond James | $20 → $17 | Maintains | Outperform |
| 11/25/2020 | 1639.13% | Canaccord Genuity | $25 → $20 | Maintains | Buy |
| 05/22/2020 | 595.65% | B. Riley Securities | $11 → $8 | Downgrades | Buy → Neutral |
| 05/15/2020 | 1639.13% | Raymond James | $25 → $20 | Maintains | Outperform |
| 03/13/2020 | 2073.91% | Stifel | $35 → $25 | Maintains | Buy |
| 03/13/2020 | 856.52% | B. Riley Securities | $28 → $11 | Maintains | Buy |
| 02/04/2020 | 1465.22% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 01/30/2020 | 1117.39% | Cantor Fitzgerald | $59 → $14 | Assumes | → Overweight |
| 07/22/2019 | 2073.91% | Laidlaw & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/12/2018 | 2334.78% | B. Riley Securities | → $28 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2023 年 7 月 24 日 | 247.83% | Maxim 集團 | → 4 美元 | 升級 | 持有 → 買入 |
| 08/08/2022 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 08/08/2022 | -13.04% | Canaccord Genu | 5 美元 → 1 美元 | 降級 | 買入 → 持有 |
| 05/18/2022 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
| 05/03/2022 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 05/03/2022 | 334.78% | 雷蒙德·詹姆 | 14 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 05/17/2021 | 1726.09% | Canaccord Genu | 20 美元 → 21 美元 | 維護 | 購買 |
| 03/19/2021 | 2073.91% | HC Wainwright & Co. | 29 美元 → 25 美元 | 維護 | 購買 |
| 01/08/2021 | 1378.26% | 雷蒙德·詹姆 | 20 美元 → 17 美元 | 維護 | 跑贏大盤 |
| 11/25/2020 | 1639.13% | Canaccord Genu | 25 美元 → 20 美元 | 維護 | 購買 |
| 05/22/2020 | 595.65% | B. 萊利證券 | 11 美元 → 8 美元 | 降級 | 買入 → 中性 |
| 05/15/2020 | 1639.13% | 雷蒙德·詹姆 | 25 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 03/13/2020 | 2073.91% | Stifel | 35 美元 → 25 美元 | 維護 | 購買 |
| 03/13/2020 | 856.52% | B. 萊利證券 | 28 美元 → 11 美元 | 維護 | 購買 |
| 02/04/2020 | 1465.22% | Craig-Hallum | → 18 美元 | 啓動覆蓋開啓 | → 購買 |
| 01/30/2020 | 1117.39% | 坎託·菲茨傑拉德 | 59 美元 → 14 美元 | 假設 | → 超重 |
| 07/22/2019 | 2073.91% | Laidlaw & Co. | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
| 2018 年 12 月 12 日 | 2334.78% | B. 萊利證券 | → 28 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Galmed Pharmaceuticals (GLMD)?
Galmed Pharmicals（GLMD）的目標價格是多少？
The latest price target for Galmed Pharmaceuticals (NASDAQ: GLMD) was reported by Maxim Group on July 24, 2023. The analyst firm set a price target for $4.00 expecting GLMD to rise to within 12 months (a possible 247.83% upside). 3 analyst firms have reported ratings in the last year.
Maxim集團於2023年7月24日公佈了Galmed Pharmicals（納斯達克股票代碼：GLMD）的最新目標股價。這家分析公司將目標股價定爲4.00美元，預計GLMD將在12個月內升至247.83％（可能上漲247.83％）。去年有3家分析公司公佈了評級。
What is the most recent analyst rating for Galmed Pharmaceuticals (GLMD)?
分析師對Galmed Pharmicals（GLMD）的最新評級是多少？
The latest analyst rating for Galmed Pharmaceuticals (NASDAQ: GLMD) was provided by Maxim Group, and Galmed Pharmaceuticals upgraded their buy rating.
Galmed Pharmicals（納斯達克股票代碼：GLMD）的最新分析師評級由Maxim集團提供，Galmed Pharmicals上調了買入評級。
When is the next analyst rating going to be posted or updated for Galmed Pharmaceuticals (GLMD)?
Galmed Pharmicals（GLMD）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Galmed Pharmicals的高管和客戶交談以及聽取財報電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Galmed Pharmicals的最新評級是在2023年7月24日提交的，因此您應該預計下一個評級將在2024年7月24日左右公佈。
Is the Analyst Rating Galmed Pharmaceuticals (GLMD) correct?
分析師對Galmed Pharmicals（GLMD）的評級正確嗎？
While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a upgraded with a price target of $0.00 to $4.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $1.15, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Galmed Pharmicals（GLMD）評級已上調，目標股價爲0.00美元至4.00美元。Galmed Pharmicals（GLMD）目前的交易價格爲1.15美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。